Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Stryker Bets $316 Million It Can Invigorate Orthovita's Biologics Biz

This article was originally published in The Gray Sheet

Executive Summary

Stryker hopes its sales force heft can push Orthovita's line of synthetic orthobiologics into a better growth position while filling important competitive gaps.

Related Content

CMS Issues List Of Potential National Coverage Determination Topics
Medical Device and In Vitro Diagnostics/Research Deals Statistics Quarterly, Q2 2011
Stryker Buys Memometal For Broader Access To $1 Bil. Extremities Market
News In Brief
FDA Panel Narrowly Supports BioMimetic's Augment Synthetic Bone Graft
After J&J-Synthes Deal, Will Orthopedic Consolidation Hit Zimmer, Stryker?
Olympus Acquires Stryker OP-1 Products, Spawns Biotech Division
Olympus Acquires Stryker OP-1 Products, Spawns Biotech Division
Struggling Orthovita Taps Distributors To Chase Outpatient Vertebroplasties
New Products In Brief





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts